Company: CYTK
Filing Date: 2025-09-03
Form Type: 8-K
Source: 0000950170-25-112570
Chunk: 0

Company: CYTOKINETICS INC
Filing Date: 2025-09-03
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

On August 31, 2025, Cytokinetics, Incorporated announced that additional data related to aficamten were presented at the European Society of Cardiology Congress 2025 in Madrid, Spain, including a pre-specified analysis of the effect of aficamten on cardiac structure and function from MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM), which was simultaneously published in the Journal of the American College of Cardiology, as well as a Late Breaking Clinical Science presentation related to the incidence and impact of atrial fibrillation (AF) associated with aficamten, which was simultaneously published in Heart Rhythm. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.